Exhibitors Search
MEDICINE PARK Co., Ltd.
Booth no.
P70
|
Exhibition
|
|KOREA LIFE SCIENCE |
|---|---|
|
Country
|
| |
|
Address
|
|304 Res. Exp. Bldg. SEOUL BIOHUB |
|
Tel
|
| |
|
Exhibits
|
| Low-molecular-weight biopolymer-based DMOAD candidate: An intra-articular injection for osteoarthritis |
|
Company Type
|
| Pharmaceutical / Drug Development Company , Biotech Venture / Startup , Regenerative Medicine Company |
Exhibitor Information
Medicine Park is an 8-year-old R&D-focused biotech venture co-founded by an M.D. specializing in rehabilitation medicine and a Ph.D. in clinical nutrition. We develop preventive and therapeutic technologies for joint and connective tissue disorders(cartilage, collagen, bone, adipose tissues) using biopolymer materials.
Beyond new drug discovery, our primary goal is to generate revenue via expedited regulatory approvals and out-licensing(post-nonclinical or Phase 1/2a) by repurposing and modifying existing pharmaceuticals with novel indications to ensure proven safety in advance.
Pipeline:
-MP101-H: A disease-modifying intra-articular injection for knee osteoarthritis(Nonclinical end stage; currently developing specifications and test methods for clinical trial material)
-MP101-K9: A canine knee pain therapeutic(Preparing for investigator-initiated pilot trials)
Fundraising: Series A(Targeting MFDS IND filing in early 2027; raising funds for Phase 1/2a trials and canine pilot trial)
Beyond new drug discovery, our primary goal is to generate revenue via expedited regulatory approvals and out-licensing(post-nonclinical or Phase 1/2a) by repurposing and modifying existing pharmaceuticals with novel indications to ensure proven safety in advance.
Pipeline:
-MP101-H: A disease-modifying intra-articular injection for knee osteoarthritis(Nonclinical end stage; currently developing specifications and test methods for clinical trial material)
-MP101-K9: A canine knee pain therapeutic(Preparing for investigator-initiated pilot trials)
Fundraising: Series A(Targeting MFDS IND filing in early 2027; raising funds for Phase 1/2a trials and canine pilot trial)
Exhibit Description
Medicine Park is developing a novel modified drug candidate (DMOAD) targeting fundamental structural disease modification rather than mere symptomatic relief for knee osteoarthritis. By reducing the molecular weight of a postbiotic biopolymer derived from lactic acid bacteria, originally used as a key component in a previously approved drug, we have eliminated the risk of allergic immune responses. Furthermore, by applying its dual mechanism of action, which modulates the intra-articular immune microenvironment to suppress synovial inflammation and cartilage matrix degradation, we are opening new possibilities in osteoarthritis treatment.
Individual Exhibit/Technology Introduction (Detailed)
-
Product Name : Biopolymer-Based DMOAD: Dual Anti-Inflammatory and Chondroprotective Intra-Articular Therapy1. Anti-inflammatory and analgesic effects through modulation of the intra-articular immune microenvironment 2. Chondroprotective effect by downregulating cartilage-degrading enzymes (MMP-3, MMP-13) and upregulating Type II collagen synthesis 3. Rapid onset and sustained duration of action as a low-molecular-weight biopolymer intra-articular injection 4. Intra-articular injection: Convenient procedure (once weekly, up to 3 consecutive injections), significantly reduced injection pain, immediate return to daily activities, and high cost-effectiveness
KYUNGYON EXHIBITION CORP.
